Skip to main content
Login
User menu
Mega menu
EASL
Resources
Resources
EASL Resources
All Resources
Basic Techniques in Experimental Hepatology at a Glance
Clinical Practice Guidelines
Congress Resources
COVID-19 Resources
EASL Molecular Tumour Boards
EASL Policy Dialogues
EASL Quiz
ePosters
EASL Journal Club
Nurses and AHPs
Online Courses
On-demand Webinars
Podcasts
Slide Decks
Webcasts
Webinars Calendar
EASL-Related Resources
EHC On-demand Webinar
ERN Rare-Liver On-demand Webinars
Baveno VII - Consensus Workshop
Baveno VII - Pediatric Research Workshop
Industry Resources
All Resources
Industry Symposia - EASL Monothematic Conference 2023
Industry Symposia - International Liver Congress
Industry Symposia - Liver Cancer Summit
Industry Symposia - NAFLD Summit 2022
Patient Resources
All Resources
COVID-19 Resources
Documents
ePosters
Infographics
Patient Guidelines
Podcasts
Slide Decks
Takeaways
Webcasts
EASL Studio
EASL Campus Connect
My Community
Explore Community
EASL Community Feed
All Topics
Community FAQ's
Create
Our Sponsors
Quiz
Quiz: A female of 70 years all with type II diabetes, hypertension and NASH
Quiz: A quarter of the global adult population is estimated to have non-alcoholic fatty liver disease (NAFLD)
EASL Molecular Tumour Board on intrahepatic cholangiocarcinoma - 23 May 2023
Quiz: Concerning newly developed patient-derived xenograft models of cholangiocarcinoma
Quiz: A portal vein thrombosis (PVT) is diagnosed in a 50 years-old man with polycythaemia vera.
Quiz: A 48-year-old female nurse presents with abdominal pain and hepatomegaly.
Quiz: Liver transplantation (LT) should be considered in any patient with end-stage liver disease.
Quiz: On routine examination a 52-year-old gynecologist with normal serum liver tests turns out to be HBs-Antigen positive with low-level viremia of HBV at 1,012 IU/ml.
Quiz: A 68-year-old man with established cirrhosis due to metabolic dysfunction associated fatty liver disease presents to the emergency room, disorientated and drowsy.
Quiz: Drug-induced liver injury (DILI) is a leading cause of clinical trial failure and drug withdrawal from the market, calling for better scalable preclinical systems to assess hepatotoxicity and guide drug safety testing.
Pagination
Previous page
‹‹
Next page
››
Explore Community
Community Stream
Easl Community Feed
My Feed
Browse Stream
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Privacy Policy
Cookie Policy